Heliogen, Inc. Announces Third Quarter 2022 Financial and Operational Results; Reports Commercial Progress on Green Hydrogen Initiatives
Heliogen, Inc. (NYSE: HLGN) announced its third quarter 2022 financial results, reporting total revenues of $3.1 million and a net loss of $27.8 million, attributed to operational growth costs. The company received a $4.1 million award from the U.S. Department of Energy for solar thermal calciner development and signed a letter of intent with Dimensional Energy for sustainable aviation fuel production. Heliogen revised its 2022 revenue guidance to $12 - $14 million, down from $20 - $25 million, due to project delays. A new green hydrogen production facility is also planned with the City of Lancaster, California.
- Received $4.1 million award from U.S. Department of Energy.
- Signed letter of intent with Dimensional Energy for sustainable aviation fuel.
- Completed initial field testing of autonomous heliostat cleaning vehicle.
- Entered MOU with City of Lancaster for a green hydrogen production facility.
- Revised 2022 revenue guidance down to $12 - $14 million from $20 - $25 million.
- Reported net loss of $27.8 million for Q3 2022.
Third Quarter 2022 Highlights
-
Selected to receive a
award from the$4.1 million U.S. Department of Energy to accelerate the large-scale development and deployment of a solar thermal calciner to decarbonize cement production - Entered into a letter of intent with Dimensional Energy for the production of sustainable aviation fuel
- Successfully completed initial field testing of ChariotAV, Heliogen’s autonomous heliostat cleaning vehicle
- Began final qualification for main production lines at Heliogen’s automated, high-volume manufacturing facility
-
Appointed industrial energy transition veteran
Barbara Burger to Heliogen’s Board of Directors
Recent Highlights
-
Entered into a memorandum of understanding (“MOU”) with the
City of Lancaster, California to build a new green hydrogen production facility deploying Heliogen’s technology
Executive Commentary
“During the third quarter,
“By signing the MOU with the
“With the passage of the Inflation Reduction Act and its
Memorandum of Understanding with the
This agreement contemplates
2022 Guidance Revision
Due to delays in project timing,
Third Quarter 2022 Financial Results
For the third quarter 2022,
Conference Call Information
The
An archive of the webcast will also be available shortly after the call on the Investor Relations section of Heliogen’s website.
About
Use of Non-GAAP Financial Information
Management uses certain financial measures, including EBITDA and Adjusted EBITDA, to evaluate our financial and operating performance that are calculated and presented on the basis of methodologies other than in accordance with GAAP. We believe these non-GAAP financial measures are useful to investors and analysts to assess our ongoing financial performance because they provide improved comparability between periods through the exclusion of certain items that we believe are not indicative of our core operating performance, enhance the overall understanding of our past financial performance and future prospects, and remove items that may obscure our underlying business results and trends. These measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP, and our calculations thereof may not be comparable to similarly titled measures reported by other companies. Please see the accompanying tables for reconciliations of the following non-GAAP financial measures for Heliogen’s current and historical results: EBITDA and Adjusted EBITDA.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical in nature, including the words “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our guidance for full-year 2022, the development of our manufacturing and production facilities, achieving our financial and operational goals, progress with potential customers, expected impacts of recent legislation and future growth opportunities. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our financial and business performance, including risk of uncertainty in our financial projections and business metrics and any underlying assumptions thereunder; (ii) our ability to execute our business model, including market acceptance of our planned products and services and achieving sufficient production volumes at acceptable quality levels and prices; (iii) our ability to access sources of capital to finance operations, growth and future capital requirements; (iv) our ability to maintain and enhance our products and brand, and to attract and retain customers; (v) our ability to scale in a cost effective manner; (vi) changes in applicable laws or regulations; (vii) the ongoing impacts of the COVID-19 pandemic and the potential impacts of Russia’s invasion of
|
|||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Revenue |
$ |
3,100 |
|
|
$ |
2,202 |
|
|
$ |
9,031 |
|
|
$ |
3,563 |
|
Cost of revenue |
|
3,423 |
|
|
|
1,375 |
|
|
|
44,061 |
|
|
|
2,736 |
|
Gross profit (loss) |
|
(323 |
) |
|
|
827 |
|
|
|
(35,030 |
) |
|
|
827 |
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Selling, general, and administrative |
|
18,268 |
|
|
|
8,687 |
|
|
|
60,733 |
|
|
|
15,099 |
|
Research and development |
|
11,168 |
|
|
|
4,618 |
|
|
|
26,448 |
|
|
|
8,891 |
|
Total operating expenses |
|
29,436 |
|
|
|
13,305 |
|
|
|
87,181 |
|
|
|
23,990 |
|
Operating loss |
|
(29,759 |
) |
|
|
(12,478 |
) |
|
|
(122,211 |
) |
|
|
(23,163 |
) |
|
|
|
|
|
|
|
|
||||||||
Interest income, net |
|
259 |
|
|
|
197 |
|
|
|
666 |
|
|
|
407 |
|
SAFE instruments remeasurement |
|
— |
|
|
|
(15,533 |
) |
|
|
— |
|
|
|
(62,993 |
) |
Gain (loss) on warrant remeasurement |
|
369 |
|
|
|
(322 |
) |
|
|
12,679 |
|
|
|
(2,604 |
) |
Other income (expense), net |
|
1,256 |
|
|
|
(140 |
) |
|
|
1,071 |
|
|
|
(312 |
) |
Net loss before taxes |
|
(27,875 |
) |
|
|
(28,276 |
) |
|
|
(107,795 |
) |
|
|
(88,665 |
) |
Income tax benefit |
|
46 |
|
|
|
— |
|
|
|
781 |
|
|
|
— |
|
Net loss |
|
(27,829 |
) |
|
|
(28,276 |
) |
|
|
(107,014 |
) |
|
|
(88,665 |
) |
Other comprehensive loss, net of taxes |
|
|
|
|
|
|
|
||||||||
Unrealized losses (gains) on available-for-sale securities |
|
(18 |
) |
|
|
7 |
|
|
|
(524 |
) |
|
|
(7 |
) |
Cumulative translation adjustment |
|
(173 |
) |
|
|
(57 |
) |
|
|
(497 |
) |
|
|
(57 |
) |
Total comprehensive loss |
$ |
(28,020 |
) |
|
$ |
(28,326 |
) |
|
$ |
(108,035 |
) |
|
$ |
(88,729 |
) |
|
|
|
|
|
|
|
|
||||||||
Loss per share |
|
|
|
|
|
|
|
||||||||
Loss per share – Basic and Diluted |
$ |
(0.14 |
) |
|
$ |
(2.45 |
) |
|
$ |
(0.57 |
) |
|
$ |
(8.32 |
) |
Weighted average number of shares outstanding – Basic and Diluted |
|
192,580,125 |
|
|
|
11,545,919 |
|
|
|
188,827,770 |
|
|
|
10,650,897 |
|
|
|||||
|
|
|
|
||
|
2022 |
|
2021 |
||
ASSETS |
|
|
|
||
Cash and cash equivalents |
$ |
35,444 |
|
$ |
190,081 |
Investments, available-for-sale |
|
124,034 |
|
|
32,332 |
Other current assets |
|
13,361 |
|
|
4,770 |
Total current assets |
|
172,839 |
|
|
227,183 |
Non-current assets |
|
44,724 |
|
|
30,265 |
Total assets |
$ |
217,563 |
|
$ |
257,448 |
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
||
Trade payables |
$ |
2,335 |
|
$ |
4,645 |
Contract liabilities |
|
8,540 |
|
|
513 |
Contract loss provisions |
|
30,526 |
|
|
397 |
Other current liabilities |
|
7,410 |
|
|
6,974 |
Total current liabilities |
|
48,811 |
|
|
12,529 |
Long-term liabilities |
|
17,501 |
|
|
30,861 |
Total liabilities |
|
66,312 |
|
|
43,390 |
Shareholders’ equity |
|
151,251 |
|
|
214,058 |
Total liabilities and shareholders’ equity |
$ |
217,563 |
|
$ |
257,448 |
Non-GAAP Financial Measures
EBITDA represents condensed consolidated net loss before (i) interest (income) expense, net, (ii) income tax expense (benefit) and (iii) depreciation and amortization expense.
Adjusted EBITDA represents EBITDA adjusted for certain significant non-cash items and items that management believes are not attributable to or indicative of our on-going operations or that may obscure our underlying results and trends.
The following reconciles net loss to EBITDA and Adjusted EBITDA for the periods as shown:
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
$ in thousands |
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Net loss |
$ |
(27,829 |
) |
|
$ |
(28,276 |
) |
|
$ |
(107,014 |
) |
|
$ |
(88,665 |
) |
Adjustments |
|
|
|
|
|
|
|
||||||||
Interest income, net |
|
(259 |
) |
|
|
(197 |
) |
|
|
(666 |
) |
|
|
(407 |
) |
Income tax benefit |
|
(46 |
) |
|
|
— |
|
|
|
(781 |
) |
|
|
— |
|
Depreciation and amortization |
|
836 |
|
|
|
138 |
|
|
|
2,289 |
|
|
|
272 |
|
EBITDA |
$ |
(27,298 |
) |
|
$ |
(28,335 |
) |
|
$ |
(106,172 |
) |
|
$ |
(88,800 |
) |
Adjustments |
|
|
|
|
|
|
|
||||||||
SAFE instruments remeasurement(1) |
|
— |
|
|
|
15,533 |
|
|
|
— |
|
|
|
62,993 |
|
(Gain) loss on warrant remeasurement(2) |
|
(369 |
) |
|
|
322 |
|
|
|
(12,679 |
) |
|
|
2,604 |
|
Share-based compensation |
|
9,972 |
|
|
|
1,485 |
|
|
|
34,478 |
|
|
|
2,049 |
|
Provision for contract losses (3) |
|
— |
|
|
|
— |
|
|
|
33,737 |
|
|
|
— |
|
Contract losses incurred (3) |
|
(342 |
) |
|
|
— |
|
|
|
(3,502 |
) |
|
|
— |
|
Change in fair value of contingent consideration (4) |
|
(1,116 |
) |
|
|
|
|
(1,063 |
) |
|
|
||||
Adjusted EBITDA |
$ |
(19,153 |
) |
|
$ |
(10,995 |
) |
|
$ |
(55,201 |
) |
|
$ |
(21,154 |
) |
(1) |
Represents the change in fair value on our SAFE instruments which were converted to common stock immediately prior to the closing of the business combination with |
|
(2) |
Represents the change in fair value on our warrant liabilities for the outstanding warrants that we assumed in the business combination with |
|
(3) | Represents contract losses with customers for which estimated costs to satisfy performance obligations exceeded considerations expected to be realized. Contract loss is reduced and recognized in cost of revenue as expenditures are incurred and related revenue is recognized. |
|
(4) | Represents the change in fair value of our contingent consideration related to an acquisition completed in 2021. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107006185/en/
Heliogen Investor Contact:
Investor Relations
Louis.Baltimore@Heliogen.com
Heliogen Media Contact:
HeliogenPR@icrinc.com
Source:
FAQ
What were Heliogen's financial results for Q3 2022?
What is the revised revenue guidance for Heliogen in 2022?
What initiatives has Heliogen announced in its recent press release?
What is the significance of the MOU with the City of Lancaster?